

Benedikt Fischer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3442256/publications.pdf>

Version: 2024-02-01

309
papers

10,250
citations

28274

55
h-index

60623

81
g-index

324
all docs

324
docs citations

324
times ranked

7409
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of opioid use disorders: a national clinical practice guideline. <i>Cmaj</i> , 2018, 190, E247-E257.	2.0	297
2	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. <i>American Journal of Public Health</i> , 2017, 107, e1-e12.	2.7	295
3	Routes of administration for cannabis use – basic prevalence and related health outcomes: A scoping review and synthesis. <i>International Journal of Drug Policy</i> , 2018, 52, 87-96.	3.3	206
4	Drug policy and the public good: evidence for effective interventions. <i>Lancet</i> , The, 2012, 379, 71-83.	13.7	205
5	Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. <i>Drug and Alcohol Dependence</i> , 2008, 93, 141-147.	3.2	180
6	Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. <i>Journal of Viral Hepatitis</i> , 2009, 16, 352-358.	2.0	162
7	The effectiveness of compulsory drug treatment: A systematic review. <i>International Journal of Drug Policy</i> , 2016, 28, 1-9.	3.3	159
8	Illicit Opioid Use in Canada: Comparing Social, Health, and Drug Use Characteristics of Untreated Users in Five Cities (OPICAN Study). <i>Journal of Urban Health</i> , 2005, 82, 250-266.	3.6	149
9	Prescription Opioid Related Misuse, Harms, Diversion and Interventions in Canada: A Review. <i>Pain Physician</i> , 2012, 3S;15, ES191-ES203.	0.4	142
10	Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. <i>Drug and Alcohol Dependence</i> , 2007, 88, 1-8.	3.2	129
11	Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world?. <i>Addiction</i> , 2014, 109, 177-181.	3.3	129
12	The Costs of Alcohol, Illegal Drugs, and Tobacco in Canada, 2002. <i>Journal of Studies on Alcohol and Drugs</i> , 2007, 68, 886-895.	1.0	126
13	Changes in illicit opioid use across Canada. <i>Cmaj</i> , 2006, 175, 1385-1385.	2.0	125
14	Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. <i>Cmaj</i> , 2009, 181, 585-589.	2.0	116
15	Health outcomes associated with crack-cocaine use: Systematic review and meta-analyses. <i>Drug and Alcohol Dependence</i> , 2017, 180, 401-416.	3.2	114
16	Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. <i>Pain Physician</i> , 2012, 15, ES191-203.	0.4	108
17	Heroin-assisted Treatment (HAT) a Decade Later: A Brief Update on Science and Politics. <i>Journal of Urban Health</i> , 2007, 84, 552-562.	3.6	107
18	Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. <i>PLoS Medicine</i> , 2019, 16, e1003002.	8.4	98

#	ARTICLE	IF	CITATIONS
19	Social costs of untreated opioid dependence. <i>Journal of Urban Health</i> , 2000, 77, 688-722.	3.6	91
20	Drug use, risk and urban order: examining supervised injection sites (SISs) as "governmentality". <i>International Journal of Drug Policy</i> , 2004, 15, 357-365.	3.3	88
21	Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. <i>PLoS ONE</i> , 2018, 13, e0190768.	2.5	88
22	CANADIAN ILLICIT OPIATE USERS' VIEWS ON METHADONE AND OTHER OPIATE PRESCRIPTION TREATMENT: AN EXPLORATORY QUALITATIVE STUDY. <i>Substance Use and Misuse</i> , 2002, 37, 495-522.	1.4	86
23	Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. <i>Cmaj</i> , 2004, 171, 235-239.	2.0	86
24	Proportional Hazards Frailty Models for Recurrent Methadone Maintenance Treatment. <i>American Journal of Epidemiology</i> , 2009, 170, 783-792.	3.4	85
25	Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: Systematic review and meta-analyses. <i>Addictive Behaviors</i> , 2014, 39, 520-531.	3.0	85
26	The opioid death crisis in Canada: crucial lessons for public health. <i>Lancet Public Health</i> , The, 2019, 4, e81-e82.	10.0	84
27	The burden of disease attributable to cannabis use in Canada in 2012. <i>Addiction</i> , 2016, 111, 653-662.	3.3	83
28	Heroin-assisted treatment as a response to the public health problem of opiate dependence. <i>European Journal of Public Health</i> , 2002, 12, 228-234.	0.3	82
29	Crack across Canada: comparing crack users and crack non-users in a Canadian multi-city cohort of illicit opioid users. <i>Addiction</i> , 2006, 101, 1760-1770.	3.3	81
30	Effective Canadian policy to reduce harms from prescription opioids: learning from past failures. <i>Cmaj</i> , 2016, 188, 1240-1244.	2.0	80
31	Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005-2011. <i>Drug and Alcohol Review</i> , 2014, 33, 19-26.	2.1	78
32	Self-perceived Health Among Canadian Opiate Users. <i>Canadian Journal of Public Health</i> , 2004, 95, 99-103.	2.3	77
33	High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005-2009. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 438-442.	1.9	77
34	Trends and changes in prescription opioid analgesic dispensing in Canada 2005-2012: an update with a focus on recent interventions. <i>BMC Health Services Research</i> , 2014, 14, 90.	2.2	77
35	The Global Diversion of Pharmaceutical Drugs-Non-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures. <i>Addiction</i> , 2010, 105, 2062-2070.	3.3	75
36	Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. <i>International Journal of Drug Policy</i> , 2022, 99, 103381.	3.3	75

#	ARTICLE	IF	CITATIONS
37	Hepatitis C virus transmission among oral crack users: viral detection on crack paraphernalia. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 29-32.	1.6	74
38	Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. <i>Drug and Alcohol Review</i> , 2008, 27, 625-632.	2.1	73
39	Medical Marijuana programs: Implications for cannabis control policy – Observations from Canada. <i>International Journal of Drug Policy</i> , 2015, 26, 15-19.	3.3	73
40	Lower Risk Cannabis Use Guidelines for Canada (LRCUG): A Narrative Review of Evidence and Recommendations. <i>Canadian Journal of Public Health</i> , 2011, 102, 324-327.	2.3	72
41	Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005–2010. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1269-1277.	1.9	72
42	Nonmedical Prescription Opioid Use and Mental Health and Pain Comorbidities: A Narrative Review. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 495-502.	1.9	70
43	Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. <i>Drug and Alcohol Dependence</i> , 2016, 161, 298-306.	3.2	70
44	Key drug use, health and socio-economic characteristics of young crack users in two Brazilian cities. <i>International Journal of Drug Policy</i> , 2013, 24, 432-438.	3.3	69
45	Eyes Wide Shut? – A Conceptual and Empirical Critique of Methadone Maintenance Treatment. <i>European Addiction Research</i> , 2005, 11, 1-14.	2.4	68
46	The Prevalence of Mental Health and Pain Symptoms in General Population Samples Reporting Nonmedical Use of Prescription Opioids: A Systematic Review and Meta-Analysis. <i>Journal of Pain</i> , 2012, 13, 1029-1044.	1.4	66
47	Injection Drug Use and the Hepatitis C Virus: Considerations for a Targeted Treatment Approach—The Case Study of Canada. <i>Journal of Urban Health</i> , 2004, 81, 428-447.	3.6	65
48	The “fentanyl epidemic”™ in Canada – Some cautionary observations focusing on opioid-related mortality. <i>Preventive Medicine</i> , 2018, 107, 109-113.	3.4	65
49	Exclusion, “risk”™, and social control—reflections on community policing and public health. <i>Geoforum</i> , 1998, 29, 187-197.	2.5	64
50	Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: A comprehensive narrative overview of English-language studies. <i>International Journal of Drug Policy</i> , 2015, 26, 352-363.	3.3	64
51	“Hard to crack”: Experiences of community integration among first- and second-generation Asian MSM in Canada.. <i>Cultural Diversity and Ethnic Minority Psychology</i> , 2013, 19, 248-256.	2.0	63
52	Illicit opioid use in the 21st century: witnessing a paradigm shift?. <i>Addiction</i> , 2007, 102, 499-501.	3.3	58
53	Illicit Opiates in Toronto: A Profile of Current Users. <i>Addiction Research</i> , 1999, 7, 377-415.	0.6	57
54	Crack Use As a Public Health Problem in Canada. <i>Canadian Journal of Public Health</i> , 2005, 96, 185-188.	2.3	57

#	ARTICLE	IF	CITATIONS
55	Prescriptions, Power and Politics: The Turbulent History of Methadone Maintenance in Canada. <i>Journal of Public Health Policy</i> , 2000, 21, 187.	2.0	55
56	Determinants of Health-Related Quality of Life of Opiate Users at Entry to Low-Threshold Methadone Programs. <i>European Addiction Research</i> , 2006, 12, 74-82.	2.4	55
57	Crude estimates of cannabis-attributable mortality and morbidity in Canada—implications for public health focused intervention priorities. <i>Journal of Public Health</i> , 2016, 38, 183-188.	1.8	54
58	Public opinion towards supervised injection facilities and heroin-assisted treatment in Ontario, Canada. <i>International Journal of Drug Policy</i> , 2007, 18, 54-61.	3.3	52
59	Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: An update 5 years later. <i>Canadian Journal of Public Health</i> , 2014, 105, e146-e149.	2.3	52
60	Cannabis legalization with strict regulation, the overall superior policy option for public health. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 541-544.	4.7	51
61	Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence. <i>Addictive Behaviors</i> , 2005, 30, 1025-1028.	3.0	50
62	Illicit Opioid Use and its Key Characteristics: A Select Overview and Evidence from a Canadian Multisite Cohort of Illicit Opioid Users (OPICAN). <i>Canadian Journal of Psychiatry</i> , 2006, 51, 624-634.	1.9	50
63	Assessing the public health impact of cannabis legalization in Canada: core outcome indicators towards an “index”™ for monitoring and evaluation. <i>Journal of Public Health</i> , 2019, 41, 412-421.	1.8	50
64	Reduction in Injection-Related HIV Risk After 6 Months in a Low-Threshold Methadone Treatment Program. <i>AIDS Education and Prevention</i> , 2007, 19, 124-136.	1.1	49
65	Cannabis Use in Canada: The Need for a “Public Health”™ Approach. <i>Canadian Journal of Public Health</i> , 2009, 100, 101-103.	2.3	48
66	Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. <i>Journal of Viral Hepatitis</i> , 2011, 18, 32-41.	2.0	48
67	Drug Policy and the Public Good. , 2018, , .		48
68	Potential risk of light and room temperature exposure to preimplantation embryos. <i>Fertility and Sterility</i> , 1988, 50, 938-944.	1.0	47
69	Multiple viral hepatitis in injection drug users and associated risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 80-85.	2.8	47
70	An overview of illegal opioid use and health services utilization in Canada. <i>Public Health</i> , 2006, 120, 320-328.	2.9	46
71	A qualitative exploration of prescription opioid injection among street-based drug users in Toronto: behaviours, preferences and drug availability. <i>Harm Reduction Journal</i> , 2008, 5, 30.	3.2	46
72	Prevalence and key covariates of non-medical prescription opioid use among the general secondary student and adult populations in Ontario, Canada. <i>Drug and Alcohol Review</i> , 2013, 32, 276-287.	2.1	44

#	ARTICLE	IF	CITATIONS
73	The Case for a Heroin Substitution Treatment Trial in Canada. Canadian Journal of Public Health, 1997, 88, 367-370.	2.3	43
74	Prescription Drug Abuse in Canada and the Diversion of Prescription Drugs into the Illicit Drug Market. Canadian Journal of Public Health, 2005, 96, 459-461.	2.3	43
75	Determinants of Property Crime Among Illicit Opiate Users Outside of Treatment Across Canada. Deviant Behavior, 2006, 27, 351-376.	1.7	43
76	Fentanyl use among street drug users in Toronto, Canada: Behavioural dynamics and public health implications. International Journal of Drug Policy, 2009, 20, 90-92.	3.3	43
77	Estimating the harms and costs of cannabis-attributable collisions in the Canadian provinces. Drug and Alcohol Dependence, 2017, 173, 185-190.	3.2	42
78	Feasibility and Outcome of HCV Treatment in a Canadian Federal Prison Population. American Journal of Public Health, 2005, 95, 1737-1739.	2.7	41
79	Changes in and characteristics of admissions to treatment related to problematic prescription opioid use in Ontario, 2004-2009. Drug and Alcohol Dependence, 2010, 109, 257-260.	3.2	40
80	Uptake, benefits of and barriers to safer crack use kit (SCUK) distribution programmes in Victoria, Canada- A qualitative exploration. International Journal of Drug Policy, 2011, 22, 292-300.	3.3	40
81	Patterns, Changes, and Trends in Prescription Opioid Dispensing in Canada, 2005-2016. Pain Physician, 2018, 1, 219-228.	0.4	40
82	Comparing Injecting and Non-Injecting Illicit Opioid Users in a Multisite Canadian Sample (OPICAN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.4	39
83	Crack use in North American cities: the neglected "epidemic"™. Addiction, 2007, 102, 1340-1341.	3.3	39
84	Non-medical Use of Prescription Opioids and Public Health in Canada. Canadian Journal of Public Health, 2008, 99, 182-184.	2.3	39
85	Cannabis Law Reform in Canada: Is the "Saga of Promise, Hesitation and Retreat" Coming to an End?1. Canadian Journal of Criminology and Criminal Justice, 2003, 45, 265-298.	0.5	38
86	Feasibility and impact of brief interventions for frequent cannabis users in Canada. Journal of Substance Abuse Treatment, 2013, 44, 132-138.	2.8	38
87	Risk creating and risk reducing: Community perceptions of supervised consumption facilities for illicit drug use. Health, Risk and Society, 2017, 19, 91-111.	1.7	38
88	Toking and driving: Characteristics of Canadian university students who drive after cannabis use- an exploratory pilot study. Drugs: Education, Prevention and Policy, 2006, 13, 179-187.	1.3	37
89	Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995. Clinical Drug Investigation, 2016, 36, 519-530.	2.2	37
90	Police Perceptions of Supervised Consumption Sites (SCSs): A Qualitative Study. Substance Use and Misuse, 2012, 47, 364-374.	1.4	36

#	ARTICLE	IF	CITATIONS
91	The opioid mortality epidemic in North America: do we understand the supply side dynamics of this unprecedented crisis?. Substance Abuse Treatment, Prevention, and Policy, 2020, 15, 14.	2.2	36
92	Prescription Opioid Use, Harms and Interventions in Canada: A Review Update of New Developments and Findings since 2010. Pain Physician, 2015, 18, E605-14.	0.4	36
93	Harms of prescription opioid use in the United States. Substance Abuse Treatment, Prevention, and Policy, 2014, 9, 43.	2.2	35
94	Addressing the stimulant treatment gap: A call to investigate the therapeutic benefits potential of cannabinoids for crack-cocaine use. International Journal of Drug Policy, 2015, 26, 1177-1182.	3.3	35
95	Correlations between opioid mortality increases related to illicit/synthetic opioids and reductions of medical opioid dispensing - exploratory analyses from Canada. BMC Public Health, 2020, 20, 143.	2.9	35
96	SUBSTITUTION THERAPY FOR HEROIN ADDICTION. Substance Use and Misuse, 2002, 37, 1149-1178.	1.4	34
97	Crack across the Americas – A massive problem in continued search of viable answers: Exemplary views from the North (Canada) and the South (Brazil). International Journal of Drug Policy, 2013, 24, 631-633.	3.3	34
98	Increasing public support for supervised injection facilities in Ontario, Canada. Addiction, 2014, 109, 946-953.	3.3	34
99	Exploring sex differences in drug use, health and service use characteristics among young urban crack users in Brazil. International Journal for Equity in Health, 2014, 13, 70.	3.5	33
100	Substance Use and Related Harms among Aboriginal People in Canada: A Comprehensive Review. Journal of Health Care for the Poor and Underserved, 2015, 26, 1110-1131.	0.8	33
101	Deaths related to the use of prescription opioids. Cmaj, 2009, 181, 881-882.	2.0	32
102	Profiling poly-substance use typologies in a multi-site cohort of illicit opioid and other drug users in Canada – a latent class analysis. Addiction Research and Theory, 2009, 17, 168-185.	1.9	32
103	Typologies of cannabis users and associated characteristics relevant for public health: a latent class analysis of data from a nationally representative Canadian adult survey. International Journal of Methods in Psychiatric Research, 2010, 19, 110-124.	2.1	32
104	Patterns, determinants and barriers of health and social service utilization among young urban crack users in Brazil. BMC Health Services Research, 2013, 13, 536.	2.2	32
105	Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence. Journal of Addiction Medicine, 2016, 10, 274-279.	2.6	32
106	Illicit drug use and harms, and related interventions and policy in Canada: A narrative review of select key indicators and developments since 2000. International Journal of Drug Policy, 2016, 27, 23-35.	3.3	32
107	Revisiting the “paradigm shift”™ in opioid use: Developments and implications 10 years later. Drug and Alcohol Review, 2018, 37, S199-S202.	2.1	32
108	Crude estimates of prescription opioid-related misuse and use disorder populations towards informing intervention system need in Canada. Drug and Alcohol Dependence, 2018, 189, 76-79.	3.2	32

#	ARTICLE	IF	CITATIONS
109	Impact of Methadone Maintenance Treatment on Women Offenders' Post-Release Recidivism. <i>European Addiction Research</i> , 2014, 20, 192-199.	2.4	31
110	â€œResurgentâ€™, â€œtwinâ€™ or â€œsilentâ€™ epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 17.	2.2	31
111	An overview of select cannabis use and supply indicators pre- and post-legalization in Canada. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 77.	2.2	31
112	Methamphetamine Injection Independently Predicts Hepatitis C Infection Among Street-Involved Youth in a Canadian Setting. <i>Journal of Adolescent Health</i> , 2009, 44, 302-304.	2.5	30
113	Charting WHOâ€™s goals for licit and illicit drugs for the year 2000 are we 'on track'?. <i>Public Health</i> , 1997, 111, 271-275.	2.9	29
114	How Drug using men who have sex with men account for substance use during Sexual Behaviours: Questioning assumptions of Hiv Prevention and Research. <i>Addiction Research and Theory</i> , 2004, 12, 213-229.	1.9	29
115	Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada. <i>Journal of Public Health Policy</i> , 2000, 21, 187-210.	2.0	29
116	Comparing Opiate Users in Methadone Treatment with Untreated Opiate Users: Results of a Follow-up Study with a Toronto Opiate User Cohort. <i>Canadian Journal of Public Health</i> , 1999, 90, 299-303.	2.3	28
117	Patterns of opioid and cocaine co-use: A descriptive study in a Canadian sample of untreated opioid-dependent individuals.. <i>Experimental and Clinical Psychopharmacology</i> , 2005, 13, 303-310.	1.8	28
118	The Cannabis Policy Framework by the Centre for Addiction and Mental Health: A proposal for a public health approach to cannabis policy in Canada. <i>International Journal of Drug Policy</i> , 2016, 34, 1-4.	3.3	28
119	Treatment of prescription opioid disorders in Canada: looking at the â€œother epidemicâ€™?. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2016, 11, 12.	2.2	28
120	Human T-lymphotropic virus 1 and 2 among people who used illicit drugs in the state of ParÃ¡i, northern Brazil. <i>Scientific Reports</i> , 2019, 9, 14750.	3.3	28
121	Use and Nonmedical Use of Prescription Opioid Analgesics in the General Population of Canada and Correlations with Dispensing Levels in 2009. <i>Pain Research and Management</i> , 2013, 18, 69-74.	1.8	27
122	A century of cannabis control in Canada. , 2020, , 89-115.		27
123	NUTT ET AL.'S HARM SCALES FOR DRUGS-ROOM FOR IMPROVEMENT BUT BETTER POLICY BASED ON SCIENCE WITH LIMITATIONS THAN NO SCIENCE AT ALL. <i>Addiction</i> , 2011, 106, 1891-1892.	3.3	26
124	Recent changes in trends of opioid overdose deaths in North America. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 66.	2.2	26
125	A Narrative Review of Recent Developments in Knowledge Translation and Implications for Mental Health Care Providers. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 160-169.	1.9	25
126	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. <i>American Journal of Public Health</i> , 2017, 107, 1277-1277.	2.7	25

#	ARTICLE	IF	CITATIONS
127	Food insecurity, chronic pain, and use of prescription opioids. <i>SSM - Population Health</i> , 2021, 14, 100768.	2.7	25
128	High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: Results from a population-level retrospective cohort study. <i>American Journal on Addictions</i> , 2014, 23, 257-264.	1.4	24
129	Policy Changes and the Methadone Maintenance Treatment System for Opioid Dependence in Ontario, 1996 to 2001. <i>Journal of Addictive Diseases</i> , 2005, 24, 39-51.	1.3	23
130	Correlations between population levels of prescription opioid use and prescription-opioid-related substance use treatment admissions in the USA and Canada since 2001. <i>Public Health</i> , 2012, 126, 749-751.	2.9	23
131	Increases in the availability of prescribed opioids in a Canadian setting. <i>Drug and Alcohol Dependence</i> , 2012, 126, 7-12.	3.2	23
132	Use of other opioids during methadone therapy: a population-based study. <i>Addiction</i> , 2012, 107, 776-780.	3.3	23
133	Some notes on the use, concept and socio-political framing of "stigma" focusing on an opioid-related public health crisis. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 54.	2.2	23
134	Prescription opioid dispensing in Canada: an update on recent developments to 2018. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 68.	2.4	23
135	Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2022, 179, 726-739.	7.2	23
136	Characterizing the "Awakening Elephant" of Prescription Opioid Misuse in North America: Epidemiology, Harms, Interventions. <i>Contemporary Drug Problems</i> , 2008, 35, 397-426.	1.6	22
137	How Many People in Canada Use Prescription Opioids Nonmedically in General and Street Drug Using Populations?. <i>Canadian Journal of Public Health</i> , 2009, 100, 104-108.	2.3	22
138	Non-medical Use of Prescription Opioids Among Ontario Adults: Data From the 2008/2009 CAMH Monitor. <i>Canadian Journal of Public Health</i> , 2011, 102, 330-335.	2.3	22
139	Policy implications of marked reversals of population life expectancy caused by substance use. <i>BMC Medicine</i> , 2016, 14, 42.	5.5	22
140	The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. <i>Contemporary Clinical Trials</i> , 2018, 69, 21-27.	1.8	22
141	Prescription Opioid Use, Harms and Interventions in Canada: A Review Update of New Developments and Findings since 2010. <i>Pain Physician</i> , 2015, 18;4, E605-E614.	0.4	22
142	Prostitutes are people too. <i>Lancet</i> , The, 2005, 366, 1264-1265.	13.7	21
143	Change in health-related quality of life of opiate users in low-threshold methadone programs. <i>Journal of Substance Use</i> , 2006, 11, 137-149.	0.7	21
144	Social, health and drug use characteristics of primary crack users in three mid-sized communities in British Columbia, Canada. <i>Drugs: Education, Prevention and Policy</i> , 2010, 17, 333-353.	1.3	21

#	ARTICLE	IF	CITATIONS
145	Prescription opioids, abuse and public health in Canada: is fentanyl the new centre of the opioid crisis?. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1334-1336.	1.9	21
146	Guidelines for public health and safety metrics to evaluate the potential harms and benefits of cannabis regulation in Canada. <i>Drug and Alcohol Review</i> , 2019, 38, 606-621.	2.1	21
147	Patterns, Changes, and Trends in Prescription Opioid Dispensing in Canada, 2005-2016. <i>Pain Physician</i> , 2018, 21, 219-228.	0.4	21
148	Assessing options for cannabis law reform: A Multi-Criteria Decision Analysis (MCDA) with stakeholders in New Zealand. <i>International Journal of Drug Policy</i> , 2022, 105, 103712.	3.3	21
149	Assessing the Prevalence of Nonmedical Prescription Opioid Use in the General Canadian Population: Methodological Issues and Questions. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 606-609.	1.9	20
150	12-month follow-up of an exploratory "brief intervention"™ for high-frequency cannabis users among Canadian university students. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2012, 7, 15.	2.2	20
151	Estimating the economic value of British Columbia's domestic cannabis market: Implications for provincial cannabis policy. <i>International Journal of Drug Policy</i> , 2012, 23, 436-441.	3.3	20
152	Structural barriers in the context of opiate substitution treatment in Germany - a survey among physicians in primary care. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2013, 8, 26.	2.2	20
153	Assessing the Impact of Methadone Maintenance Treatment (MMT) on Post-release Recidivism among Male Federal Correctional Inmates in Canada. <i>Criminal Justice and Behavior</i> , 2014, 41, 380-394.	1.8	20
154	Medical marijuana programs " Why might they matter for public health and why should we better understand their impacts?. <i>Preventive Medicine Reports</i> , 2015, 2, 53-56.	1.8	20
155	Assessing service and treatment needs and barriers of youth who use illicit and non-medical prescription drugs in Northern Ontario, Canada. <i>PLoS ONE</i> , 2019, 14, e0225548.	2.5	20
156	Development of preimplantation rabbit embryos in uterine flushing-supplemented culture media. <i>Molecular Reproduction and Development</i> , 1990, 27, 216-223.	2.0	19
157	Depression " A major but neglected consequence contributing to the health toll from prescription opioids?. <i>Psychiatry Research</i> , 2016, 243, 331-334.	3.3	19
158	Realistically furthering the goals of public health by cannabis legalization with strict regulation: Response to Kalant. <i>International Journal of Drug Policy</i> , 2016, 34, 11-16.	3.3	19
159	Characterization of hepatitis B virus infection in illicit drug users in the Marajó Archipelago, northern Brazil. <i>Archives of Virology</i> , 2017, 162, 227-233.	2.1	19
160	Injection drug use and preventive measures: a comparison of Canadian and western European jurisdictions over time. <i>Cmaj</i> , 2000, 162, 1709-13.	2.0	19
161	Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2023, 53, 3858-3868.	4.5	19
162	"Opioid Drought"™, Canadian-style? Potential implications of the "natural experiment"™ of delisting Oxycontin in Canada. <i>International Journal of Drug Policy</i> , 2012, 23, 495-497.	3.3	18

#	ARTICLE	IF	CITATIONS
163	Comparing key characteristics of young adult crack users in and out-of-treatment in Rio de Janeiro, Brazil. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2014, 9, 2.	2.2	18
164	Initial indicators of the public health impacts of non-medical cannabis legalization in Canada. <i>EClinicalMedicine</i> , 2020, 20, 100294.	7.1	18
165	Compulsory Drug Treatment in Canada: Historical Origins and Recent Developments. <i>European Addiction Research</i> , 2002, 8, 61-68.	2.4	17
166	Safer Injection Facilities (SIFs) for Injection Drug Users (IDUs) in Canada. <i>Canadian Journal of Public Health</i> , 2002, 93, 336-338.	2.3	17
167	Prevalence of pain among nonmedical prescription opioid users in substance use treatment populations: systematic review and meta-analyses. <i>Pain Physician</i> , 2013, 16, E671-84.	0.4	17
168	Effects of asynchrony on rabbit blastocyst development. <i>Reproduction</i> , 1989, 86, 479-491.	2.6	16
169	Drugs, Communities, and "Harm Reduction" in Germany: The New Relevance of "Public Health" Principles in Local Responses. <i>Journal of Public Health Policy</i> , 1995, 16, 389.	2.0	16
170	Comparing Medical and Recreational Cannabis Users on Socio-Demographic, Substance and Medication Use, and Health and Disability Characteristics. <i>European Addiction Research</i> , 2017, 23, 129-135.	2.4	16
171	Hepatitis C virus infection among illicit drug users in an archipelago of the Amazon. <i>Archives of Virology</i> , 2018, 163, 617-622.	2.1	16
172	Prevalence and risk factors for HIV-1 infection in people who use illicit drugs in northern Brazil. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2020, 114, 213-221.	1.8	16
173	Prohibition, public health and a window of opportunity: An analysis of Canadian drug policy, 1985-1997. <i>Policy Studies</i> , 1999, 20, 197-210.	1.6	15
174	Predictors of methadone maintenance treatment utilization in a multisite cohort of illicit opioid users (OPICAN). <i>Journal of Substance Abuse Treatment</i> , 2008, 34, 340-346.	2.8	15
175	Factors Associated with High-Frequency Cannabis Use and Driving among a Multi-site Sample of University Students in Ontario. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2014, 56, 185-200.	0.5	15
176	Driving under the influence of prescription opioids: Self-reported prevalence and association with collision risk in a large Canadian jurisdiction. <i>Accident Analysis and Prevention</i> , 2018, 121, 14-19.	5.7	15
177	Thinking Beyond Legalization: The Case for Expanding Evidence-Based Options for Cannabis Use Disorder Treatment in Canada. <i>Canadian Journal of Psychiatry</i> , 2019, 64, 82-87.	1.9	15
178	Hepatitis C virus infection status and associated factors among a multi-site sample of people who used illicit drugs in the Amazon region. <i>BMC Infectious Diseases</i> , 2019, 19, 634.	2.9	15
179	Illicit opiates and crime: Results of an untreated user cohort study in Toronto. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2001, 43, 197-217.	0.3	15
180	Prevalence and Associated Factors of Hepatitis C Infection (HCV) in a Multi-site Canadian Population of Illicit Opioid and Other Drug Users (OPICAN). <i>Canadian Journal of Public Health</i> , 2007, 98, 130-133.	2.3	14

#	ARTICLE	IF	CITATIONS
181	Nonmedical Use of Prescription Opioids: Furthering a Meaningful Research Agenda. <i>Journal of Pain</i> , 2008, 9, 490-493.	1.4	14
182	Prescription drug abuse and methods of diversion: The potential role of a pharmacy network. <i>Journal of Substance Use</i> , 2009, 14, 75-83.	0.7	14
183	Prevalence and trends of non-medical opioid and other drug use histories among federal correctional inmates in methadone maintenance treatment in Canada. <i>Drug and Alcohol Dependence</i> , 2012, 124, 172-176.	3.2	14
184	Assessing the prevalence of non-medical prescription opioid use in the Canadian general adult population: evidence of large variation depending on survey questions used. <i>BMC Psychiatry</i> , 2013, 13, 6.	2.6	14
185	Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users in Germany. <i>International Journal of Drug Policy</i> , 2016, 29, 57-65.	3.3	14
186	An easy-to-build, low-budget point-of-care ultrasound simulator: from Linux to a web-based solution. <i>The Ultrasound Journal</i> , 2017, 9, 4.	2.0	14
187	“Delisting” OxyContin® to reduce prescription opioid-related harms in Ontario (Canada) gauging effects 5 years later. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1040-1043.	1.9	14
188	Legalisation of non-medical cannabis in Canada: will supply regulations effectively serve public health?. <i>Lancet Public Health</i> , The, 2017, 2, e536-e537.	10.0	14
189	Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 37-43.	0.3	14
190	Non-medical opioid use, harms, and interventions in Canada – a 10-year update on an unprecedented substance use-related public health crisis. <i>Drugs: Education, Prevention and Policy</i> , 2020, 27, 118-122.	1.3	14
191	A heroin prescription trial: Case studies from Montreal and Vancouver on crime and disorder in the surrounding neighbourhoods. <i>International Journal of Drug Policy</i> , 2010, 21, 28-35.	3.3	13
192	“What a pity!” – Exploring the use of “pilhão” as harm reduction among crack users in Salvador, Brazil. <i>Drugs: Education, Prevention and Policy</i> , 2011, 18, 382-386.	1.3	13
193	Crack Pipe Sharing in Context: How Sociostructural Factors Shape Risk Practices among Noninjection Drug Users. <i>Contemporary Drug Problems</i> , 2013, 40, 481-503.	1.6	13
194	Characteristics of clients using a community-based drug treatment service (“CAPS-AD”) in Brazil: An exploratory study. <i>International Journal of Drug Policy</i> , 2016, 31, 99-103.	3.3	13
195	Correlations between population-levels of prescription opioid dispensing and related deaths in Ontario (Canada), 2005–2016. <i>Preventive Medicine</i> , 2018, 116, 112-118.	3.4	13
196	Facing the option for the legalisation of cannabis use and supply in New Zealand: An overview of relevant evidence, concepts and considerations. <i>Drug and Alcohol Review</i> , 2020, 39, 555-567.	2.1	13
197	Drug treatment courts in Canada: an evidence-based review. <i>Hiv/aids Policy * Law Review / Canadian Hiv/aids Legal Network</i> , 2007, 12, 12-7.	0.0	13
198	Embryonic development and incidence of aneuploidy in two rabbit strains of different fecundity. <i>Reproduction</i> , 1991, 92, 41-46.	2.6	12

#	ARTICLE	IF	CITATIONS
199	Prevalence and Characteristics of Substance Use Among Chinese and South Asians in Canada. <i>Journal of Ethnicity in Substance Abuse</i> , 2011, 10, 39-47.	0.9	12
200	Introducing the evidence-based population health tool of the Lower-Risk Cannabis Use Guidelines to Brazil. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 550-555.	1.7	12
201	The Lower-Risk Cannabis Use Guidelines™ (LRCUG) recommendations: How are Canadian cannabis users complying?. <i>Preventive Medicine Reports</i> , 2020, 20, 101187.	1.8	12
202	Toward a “Post-Legalization” Criminology for Cannabis: A Brief Review and Suggested Agenda for Research Priorities. <i>Contemporary Drug Problems</i> , 2021, 48, 58-74.	1.6	12
203	Recent Developments in Prescription Opioid-related Dispensing and Harm Indicators in Ontario, Canada. <i>Pain Physician</i> , 2015, 18, E659-62.	0.4	12
204	Prescription opioid prescribing, use/misuse, harms and treatment among Aboriginal people in Canada: a narrative review of available data and indicators. <i>Rural and Remote Health</i> , 2016, 16, 3974.	0.5	12
205	Health and Social Services Accessed by a Cohort of Canadian Illicit Opioid Users Outside of Treatment. <i>Canadian Journal of Public Health</i> , 2006, 97, 166-170.	2.3	11
206	Drug-related Overdose Deaths in British Columbia and Ontario, 1992–2004. <i>Canadian Journal of Public Health</i> , 2006, 97, 384-387.	2.3	11
207	Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada. <i>CMAJ Open</i> , 2013, 1, E68-E76.	2.4	11
208	Cannabis vaping and public health—some comments on relevance and implications. <i>Addiction</i> , 2015, 110, 1705-1706.	3.3	11
209	Considering the health and social welfare impacts of non-medical cannabis legalization. <i>World Psychiatry</i> , 2020, 19, 187-188.	10.4	11
210	Consideration of a North American heroin-assisted clinical trial for the treatment of opiate-dependent individuals. <i>International Journal of Drug Policy</i> , 2000, 11, 357-370.	3.3	10
211	[Commentary] UNDERSTANDING THE PARAMETERS OF NON-MEDICAL USE OF PRESCRIPTION DRUGS: MOVING BEYOND MERÉ NUMBERS. <i>Addiction</i> , 2007, 102, 1931-1932.	3.3	10
212	Beyond the barriers: marking the place for marijuana use at a Canadian high school. <i>Journal of Youth Studies</i> , 2008, 11, 47-64.	2.3	10
213	Should heroin be prescribed to heroin misusers? Yes. <i>BMJ: British Medical Journal</i> , 2008, 336, 70-70.	2.3	10
214	Thinking the unthinkable: Could the increasing misuse of prescription opioids among street drug users offer benefits for public health?. <i>Public Health</i> , 2009, 123, 145-146.	2.9	10
215	Research, Policy Development, and Progress: Antisocial Behaviour and the Automobile. <i>Canadian Public Policy/ Analyse De Politiques</i> , 2010, 36, S81-S93.	1.6	10
216	Factors Associated with Treatment Compliance and its Effects on Retention among Participants in a Court-Mandated Treatment Program. <i>Contemporary Drug Problems</i> , 2010, 37, 289-313.	1.6	10

#	ARTICLE	IF	CITATIONS
217	Reductions in non-medical prescription opioid use among adults in Ontario, Canada: are recent policy interventions working?. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2013, 8, 7.	2.2	10
218	Substance Use, Health, and Functioning Characteristics of Medical Marijuana Program Participants Compared to the General Adult Population in Ontario (Canada). <i>Journal of Psychoactive Drugs</i> , 2017, 49, 31-38.	1.7	10
219	Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies. <i>European Neuropsychopharmacology</i> , 2021, 51, 106-131.	0.7	10
220	Public Opinion towards Cannabis Control in Ontario: Strong but Diversified Support for Reforming Control of Both Use and Supply. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2016, 58, 443-459.	0.5	10
221	Illicit Opioid Use and Treatment for Opioid Dependence: Challenges for Canada and beyond. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 621-623.	1.9	9
222	Hepatitis C, Illicit Drug Use and Public Health. <i>Canadian Journal of Public Health</i> , 2006, 97, 485-488.	2.3	9
223	Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1039-1042.	1.6	9
224	The impact of medical and non-medical prescription opioid use on motor vehicle collision risk. <i>Transportation Research Part F: Traffic Psychology and Behaviour</i> , 2017, 47, 155-162.	3.7	9
225	Lower-Risk Cannabis Use Guidelines: Adherence in Canada and the U.S.. <i>American Journal of Preventive Medicine</i> , 2020, 59, e211-e220.	3.0	9
226	Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 12.	2.2	9
227	Cannabis use, legalization and youth health. <i>Cmaj</i> , 2017, 189, E971-E972.	2.0	8
228	Emerging prospects for non-medical cannabis legalisation in New Zealand: An initial view and contextualization. <i>International Journal of Drug Policy</i> , 2020, 76, 102632.	3.3	8
229	Examining correlations between opioid dispensing and opioid-related hospitalizations in Canada, 2007-2016. <i>BMC Health Services Research</i> , 2020, 20, 677.	2.2	8
230	Oral HPV among people who use crack-cocaine: prevalence, genotypes, risk factors, and key interventions in a remote Northern Brazilian region. <i>Clinical Oral Investigations</i> , 2021, 25, 759-767.	3.0	8
231	Why comparative epidemiological indicators suggest that New Zealand is unlikely to experience a severe opioid epidemic. <i>International Journal of Drug Policy</i> , 2021, 93, 103166.	3.3	8
232	Marijuana, juveniles, and the police: What high-school students believe about detection and enforcement. <i>Canadian Journal of Criminology and Criminal Justice</i> , 1998, 40, 401-420.	0.3	8
233	Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies. <i>Psychopharmacology</i> , 2022, 239, 1211-1230.	3.1	8
234	Prescription opioid abuse: what is the real problem and how do we fix it?. <i>Canadian Family Physician</i> , 2011, 57, 1241-2, e403-5.	0.4	8

#	ARTICLE	IF	CITATIONS
235	Patterns of methadone maintenance treatment provision in Ontario: Policy success or pendulum excess?. <i>Canadian Family Physician</i> , 2018, 64, e95-e103.	0.4	8
236	Drugs, communities, and "harm reduction" in Germany: the new relevance of "public health" principles in local responses. <i>Journal of Public Health Policy</i> , 1995, 16, 389-411.	2.0	8
237	Editorial. <i>European Addiction Research</i> , 2002, 8, 52-53.	2.4	7
238	<i>Drug Policy and the Public Good</i>: a summary of the second edition. <i>Addiction</i> , 2019, 114, 1941-1950.	3.3	7
239	Applying principles of injury and infectious disease control to the opioid mortality epidemic in North America: critical intervention gaps. <i>Journal of Public Health</i> , 2020, 42, 848-852.	1.8	7
240	The Devil Is in the Details! On Regulating Cannabis Use in Canada Based on Public Health Criteria Comment on "Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts". <i>International Journal of Health Policy and Management</i> , 2017, 6, 173-176.	0.9	7
241	Injection Drug Use, Multiple Hepatitis Virus Infections, and Migration: A German Study. <i>Substance Use and Misuse</i> , 2007, 42, 1353-1365.	1.4	6
242	Characteristics and predictors of health problems from use among high-frequency cannabis users in a Canadian university student population. <i>Drugs: Education, Prevention and Policy</i> , 2012, 19, 49-58.	1.3	6
243	Reflections on Pollini et al. (2017)â€”Implications for Interventions for Driving While Using Psychotropic Medications With Impairment Risk. <i>Journal of Studies on Alcohol and Drugs</i> , 2017, 78, 814-816.	1.0	6
244	Sustained Reduction in Sexual Behavior that May Pose a Risk of HIV Transmission Following Diagnosis During Early HIV Infection Among Gay Men in Vancouver, British Columbia. <i>AIDS and Behavior</i> , 2018, 22, 2068-2078.	2.7	6
245	Tramadol dispensing patterns and trends in Canada, 2007â€”2016. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 396-400.	1.9	6
246	Hepatitis B Virus Infection among People Who Use Illicit Drugs: Prevalence, Genotypes and Risk Factors in the State of AmapÃ¡, Northern Brazil. <i>Substance Use and Misuse</i> , 2020, 55, 1633-1639.	1.4	6
247	Patterns, trends and determinants of medical opioid utilization in Canada 2005â€”2020: characterizing an era of intensive rise and fall. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 65.	2.2	6
248	New Zealand's 'Cannabis Legalisation and Regulation Bill': an evidence-based assessment and critique of essential regulatory components towards policy outcomes. <i>New Zealand Medical Journal</i> , 2020, 133, 103-111.	0.5	6
249	Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study. <i>BMC Public Health</i> , 2022, 22, 436.	2.9	6
250	Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2022, 17, .	1.6	6
251	Hepatitis C treatment in a Canadian federal correctional population: Preliminary feasibility and outcomes. <i>International Journal of Prisoner Health</i> , 2005, 1, 13-18.	0.9	5
252	Local Drugâ€”Crime Dynamics in a Canadian Multi-Site Sample of Untreated Opioid Users. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2007, 49, 341-373.	0.5	5

#	ARTICLE	IF	CITATIONS
253	Preventive interventions targeting cannabis use and related harms in people with psychosis: A systematic review. <i>Microbial Biotechnology</i> , 2020, 15, 1439-1453.	1.7	5
254	“Safer opioid distribution” as an essential public health intervention for the opioid mortality crisis “ Considerations, options and examples towards broad-based implementation. <i>Public Health in Practice</i> , 2020, 1, 100016.	1.5	5
255	New Zealand's failed cannabis legalization referendum “ implications for cannabis policy reform. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 7, 100080.	2.9	5
256	Proposals for Decriminalization of Illicit Drug Use: Considering a Combination of <i>decriminalization</i> , Diversion and Devil-with-many-details for Health-oriented Policy Reform. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 13-15.	1.9	5
257	Hepatitis E Virus in People Who Use Crack-Cocaine: A Cross-Sectional Study in a Remote Region of Northern Brazil. <i>Viruses</i> , 2021, 13, 926.	3.3	5
258	Youth Cannabis use and Legalization in Canada - Reconsidering the Fears, Myths and Facts Three Years In. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2021, 30, 191-196.	0.6	5
259	Exploring Drug Sourcing among Regular Prescription Opioid Users in Canada: Data from Toronto and Victoria. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2009, 51, 55-72.	0.5	4
260	A call for greater policy and regulatory coherence for an expanding menu of legal psychoactive substances. <i>Drug and Alcohol Review</i> , 2020, 39, 737-742.	2.1	4
261	Factors associated with crack-cocaine early initiation: a Brazilian multicenter study. <i>BMC Public Health</i> , 2021, 21, 781.	2.9	4
262	Detection and Genetic Characterization of Hepatitis B and D Viruses: A Multi-Site Cross-Sectional Study of People Who Use Illicit Drugs in the Amazon Region. <i>Viruses</i> , 2021, 13, 1380.	3.3	4
263	Adiponectin stimulates glucose uptake in mouse blastocysts and embryonic carcinoma cells. <i>Reproduction</i> , 2020, 159, 227-239.	2.6	4
264	Methadone treatment in Ontario after the 1996 regulation reforms. Results of a physician survey. <i>Annales De Médecine Interne</i> , 2002, 153, 2S11-21.	0.2	4
265	Conceptualizing and considering Cannabis-Related “Harm-to-Others”: The Role of Cannabis-Related Violence. <i>Substance Use and Misuse</i> , 2022, 57, 1488-1491.	1.4	4
266	Ultrastructural and Autoradiographic study of Preimplantation rabbit embryos grown in conventional or uterine flushing-supplemented culture media. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1992, 28, 337-347.	1.5	3
267	Potential public health impacts of medical cannabis availability on opioid-related harms? Urgent but un-answered questions from Canada. <i>International Journal of Drug Policy</i> , 2019, 73, 96-99.	3.3	3
268	A decade of extreme oscillations in opioid control and availability: implications for public health in a Canadian setting. <i>Journal of Public Health Policy</i> , 2020, 41, 214-220.	2.0	3
269	Comparison of Crude Population-Level Indicators of Opioid Use and Related Harm in New Zealand and Ontario (Canada). <i>Pain and Therapy</i> , 2021, 10, 15-23.	3.2	3
270	Evaluating the intended and unintended consequences of opioid-prescribing interventions on primary care in British Columbia, Canada: protocol for a retrospective population-based cohort study. <i>BMJ Open</i> , 2020, 10, e038724.	1.9	3

#	ARTICLE	IF	CITATIONS
271	Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada. <i>International Journal of Drug Policy</i> , 2022, 100, 103480.	3.3	3
272	Applying the socio-ecological model to understand community reintegration experiences among individuals on opioid agonist treatment (OAT) released from federal incarceration in Ontario, Canada. <i>SSM Qualitative Research in Health</i> , 2022, , 100083.	1.5	3
273	Health harms of non-medical prescription opioid use: A systematic review. <i>Drug and Alcohol Review</i> , 2022, 41, 941-952.	2.1	3
274	MAKING SPACE FOR CANNABIS POLICY EXPERIMENTS. <i>Addiction</i> , 2011, 106, 1192-1193.	3.3	2
275	Brief Intervention Experiences of Young High-Frequency Cannabis Users in a Canadian Setting. <i>Contemporary Drug Problems</i> , 2012, 39, 49-72.	1.6	2
276	Reflections Regarding Future Cannabis Use Among High-Frequency Users in a Canadian University Student Population. <i>Journal of Research on Adolescence</i> , 2014, 24, 598-607.	3.7	2
277	Considerations towards a population health approach to reduce prescription opioid-related harms (with a primary focus on Canada). <i>Drugs: Education, Prevention and Policy</i> , 2015, 22, 60-65.	1.3	2
278	Policy Measures for Prescription Opioids and Harms: Enough to Protect Public Health? A Comment on Yanovitzky (2016) and Piper et al. (2016). <i>Journal of Studies on Alcohol and Drugs</i> , 2016, 77, 566-567.	1.0	2
279	Non-medical cannabis use among Indigenous Canadians: A systematic review of prevalence and associated factors. <i>International Journal of Drug Policy</i> , 2021, 90, 103081.	3.3	2
280	Correlations between Changes in Medical Opioid Dispensing and Contributions of Fentanyl to Opioid-Related Overdose Fatalities: Exploratory Analyses from Canada. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7507.	2.6	2
281	Sourcing of opioid analgesics for nonmedical use: Are veterinarians the latest frontier?. <i>Journal of Opioid Management</i> , 2018, 14, 77-79.	0.5	2
282	Spread of Human T-Lymphotropic Virus 1 and 2 Among Relatives of People Who Use Illicit Drugs in Northern Brazil. <i>Frontiers in Microbiology</i> , 2022, 13, .	3.5	2
283	Some Reflections on the Relationship of Risk, Harm and Responsibility in Recent Tobacco Lawsuits, and Implications for Public Health. <i>Canadian Journal of Public Health</i> , 2001, 92, 7-8.	2.3	1
284	Dealing with prostitution in Canada. <i>Cmaj</i> , 2005, 172, 13-14.	2.0	1
285	Commentary on Ware and St Arnaud-Trempe (2010): Nabilone abuse in Canada? Nature provides an effective prevention program. <i>Addiction</i> , 2010, 105, 504-505.	3.3	1
286	High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: Results from a population-level retrospective cohort study. <i>American Journal on Addictions</i> , 2013, 23, n/a-n/a.	1.4	1
287	Considering prescription opioid-related harms in the population: Response to commentaries. <i>Addiction</i> , 2014, 109, 186-188.	3.3	1
288	On the relationship between epidemiology and policy. <i>Addiction</i> , 2016, 111, 1687-1688.	3.3	1

#	ARTICLE	IF	CITATIONS
289	Commentary on Fazel <i>et al</i> . (2017): High levels of substance use disorders among correctional inmates—some implications for interventions of the review data from Fazel <i>et al</i> .. <i>Addiction</i> , 2017, 112, 1740-1741.	3.3	1
290	Fischer <i>et al.</i> Respond. <i>American Journal of Public Health</i> , 2017, 107, e26-e27.	2.7	1
291	Reflections on the Impending Lawsuits by Governments Against Pharmaceutical Opioid Producers in Canada. <i>Canadian Journal of Addiction</i> , 2020, 11, 25-27.	0.4	1
292	The Lower-Risk Cannabis Use Guidelines (LRCUG): A ready-made targeted prevention tool for cannabis in New Zealand. <i>Public Health in Practice</i> , 2020, 1, 100046.	1.5	1
293	Examining a migration-based phenomenon of heroin use in an urban drug scene in Sao Paulo, Brazil. <i>International Journal of Migration, Health and Social Care</i> , 2021, 17, 274-285.	0.5	1
294	Drug sentencing in Brazil: factors influencing sentencing outcomes in the criminal courts of Recife/PE. <i>Journal of Criminological Research, Policy and Practice</i> , 2021, ahead-of-print, .	0.3	1
295	Recent Developments in Prescription Opioid-related Dispensing and Harm Indicators in Ontario, Canada. <i>Pain Physician</i> , 2015, 18;4, E662-E662.	0.4	1
296	Socio-demographic, health and drug use characteristics among people with different frequency patterns of cannabis use in Brazil. <i>Drugs: Education, Prevention and Policy</i> , 2023, 30, 425-433.	1.3	1
297	Evaluating the population-level effects of oxycodone restrictions on prescription opioid utilization in Ontario. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .	1.9	1
298	Effects of Environmental Pollutants on Reproduction, Euroconference Halle, 11–13 April 1997. <i>Reproduction in Domestic Animals</i> , 1998, 33, 1-3.	1.4	0
299	Heroin prescription for opioid addicts. <i>Lancet, The</i> , 2002, 359, 890.	13.7	0
300	Illicit Opioid Use and its Key Characteristics: A Select Overview and Evidence from a Canadian Multisite Cohort of Illicit Opioid Users. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 335-336.	1.9	0
301	Factors associated with recidivism among adolescents girls in conflict with the law in an institution in Brasília, Federal District, Brazil. <i>Cadernos De Saude Pública</i> , 2015, 31, 2569-2576.	1.0	0
302	Assessing service and treatment needs of young people who use illicit and non-medical prescription drugs living in Northern Ontario, Canada. <i>F1000Research</i> , 0, 7, 1644.	1.6	0
303	Assessing service and treatment needs of young people who use illicit and non-medical prescription drugs living in Northern Ontario, Canada. <i>F1000Research</i> , 2018, 7, 1644.	1.6	0
304	The New Zealand Government Inquiry Into Mental Health And Addiction's recommendations on substance use: some reflections from the science perspective. <i>New Zealand Medical Journal</i> , 2019, 132, 65-70.	0.5	0
305	Trends in dispensing of individual prescription opioid formulations, Canada 2005–2020. <i>Journal of Pharmaceutical Policy and Practice</i> , 2022, 15, 27.	2.4	0
306	Title is missing!. , 2019, 16, e1003002.		0

#	ARTICLE	IF	CITATIONS
307	Title is missing!. , 2019, 16, e1003002.		0
308	Title is missing!. , 2019, 16, e1003002.		0
309	Title is missing!.. , 2019, 16, e1003002.		0